About US
Contact us
-
Bayer and Regeneron to develop potential drug for wet age-related macular degenerationBayer HealthCare and Regeneron Pharmaceuticals have agreed to collaborate on the development of a new antibody to platelet-derived growth factor receptor beta (PDGFR-ß) as a potential combinatio2014/1/15
-
Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus TherapeuticsEli Lilly and Companyhas announced that, based on positive PhaseII data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a poten2014/1/15
-
Alnylam buys Merck's Sirna TherapeuticsAlnylam Pharmaceuticals has acquired Merck's subsidiary Sirna Therapeutics, comprising intellectual property and RNAi assets, including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate2014/1/14
-
Lonza Extends Partnership with Pharmacyclics to Support Manufacturing of Recently Approved Oncology Therapeutic, IMBRUVICALonza, a leading supplier in Chemical Development and Manufacturing, has established an agreement with Pharmacyclics, Inc. to support the commercial and clinical production of its first-in-class oral2014/1/14
-
USP Proposal on Temperature Control During Storage and DistributionThe article provides a brief overview of drug product stability studies and practices with focus on temperature control during storage and distribution. The authors state that "recent stability studie2014/1/13
-
GSK's Mekinist-Tafinlar combination gets FDA accelerated approval for melanoma treatmentGlaxoSmithKline (GSK) has received approval from the US Food and Drug Administration (FDA) for the use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for treatment of patients with2014/1/13
-
BioLineRx and JHL Biotech partner to develop type 1 diabetes treatmentIsrael-based clinical-stage biopharmaceutical firm BioLineRx has entered into a collaboration with Taiwanese firm JHL Biotech for the joint development and commercialisation of BL-9020, a new monoclon2014/1/10
-
Catalent and Adamas Pharmaceuticals Enter Phase III Clinical Trials Manufacturing AgreementCatalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, andAdamas Pharmaceuticals Inc., have announced2014/1/10
-
Horizon and AstraZeneca collaborate on development of new cancer drugsUK-based Horizon Discovery and British-Swedish drug manufacturer AstraZeneca have entered into a research, collaboration and licensing agreement to explore a range of oncology-relevant genotypes in or2014/1/9
-
Immunocore and MedImmune Enter Immunother​apy Agreement to Develop Novel Cancer TherapiesImmunocore Ltd, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, has entered into an oncology research collaboration and licensing agreement2014/1/9